Pancreatic Cancer Trial, Recruiting NCT05802394 Sponsor: Peking Union Medical College Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05802394
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic cancer through a tissue sample (biopsy), where the tumour is either on the borderline of being removable by surgery, or has grown into nearby areas but has not spread to distant parts of the body.
  • People for whom doctors have planned treatment aimed at shrinking the tumour enough to make surgery possible.
  • People of any gender aged 18 years or older.
  • People with a general health and activity level rated at 2 or below on a standard medical scale, meaning they are able to care for themselves even if they cannot do heavy physical work (confirm with trial site).
  • People whose doctors expect them to live for at least 3 months or more.

Who may not be able to join:

  • People whose pancreatic cancer is a type other than ductal adenocarcinoma (the most common type of pancreatic cancer).
  • People who have already received any cancer-fighting drug treatment before starting their first round of chemotherapy for this cancer.
  • People who passed away or could not be contacted for follow-up within one month of starting their first chemotherapy treatment.
  • People who have another separate primary cancer diagnosis at the same time.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chunmei Bai, MD, Peking Union Medical College Hospital

Phone: 010-69158764

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 February 2023
Est. completion
1 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Resection rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov